The change of paradigm in the treatment of HER2-positive breast cancer with the development of newgeneration antibody-drug conjugates  

作　　者：Santiago Escriva-de-Romani Cristina Saura 

机构地区：[1]Medical Oncology Service,Breast Cancer Unit,Vall d’Hebron Institute of Oncology(VHIO),Passeig de la Vall d’Hebron,119,Barcelona 08035,Spain

出　　处：《Cancer Drug Resistance》2023年第1期45-58,共14页癌症耐药（英文）

摘　　要：HER2-positive breast cancer is an aggressive disease.As a result of the development of specific HER2-targeted therapies,such as trastuzumab,more than 20 years ago,the prognosis of these patients has improved.Metastatic HER2-positive breast cancer patients are achieving better survival rates upon treatment with anti-HER2 therapies than patients with HER2-negative disease.Double HER2 blockade with trastuzumab and pertuzumab combined with a taxane achieved an unprecedented survival of over 57 months in first-line patients.Trastuzumab emtansine,the first antibody-drug conjugate approved for patients in second-line treatment was a potent cytotoxic agent bound to trastuzumab and is currently a standard therapeutic strategy.Despite the progress in treatment development,most patients develop resistance and eventually relapse.Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties,such as trastuzumab deruxtecan and trastuzumab duocarmazine,which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer.

关 键 词：Breast cancer HER2-positive ADCS New drugs Mechanisms of resistance 

分 类 号：R737.9[医药卫生—肿瘤]